Head-to-head evidence
ACI-35.030 vs BMS-986446
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Tau (monoclonal antibody) · full Alzheimer's Disease pipeline
ACI-35.030
Developed by AC Immune and partners
NCT04445831 · Phase 1/2 · completed
This was a randomized, quadruple-blinded, placebo-controlled study, which is a strong design foundation, but the enrollment was very small (57 participants split across seven arms, several with only 4-6 subjects), and the primary endpoints were safety/tolerability counts and antibody-titer levels rather than a hard clinical or cognitive outcome - cognitive and functional scales (CDR-SB, RBANS, NPI) were only exploratory and their results were not even posted. Because the primary comparisons here are immunogenicity/safety readouts rather than a statistically tested clinical efficacy endpoint, this evidence is real but limited.
BMS-986446
Developed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT06268886 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ACI-35.030's landscape · BMS-986446's landscape